NeuroOne Reports 16.3% Revenue Growth but Faces Increased Losses in Q3 Fiscal 2026

NeuroOne Medical Technologies Corporation reported its financial results for the third quarter of fiscal 2026, revealing a product revenue of $1.97 million for the three months ending June 30, 2026, an increase of 16.3% from $1.70 million in the same period last year. For the nine months ended June 30, 2026, total product revenue reached $6.73 million, up from $6.36 million in the prior year. Despite this growth in revenue, the company continued to experience significant losses, reporting a net loss of $2.01 million for the quarter, compared to a loss of $1.50 million in the same quarter of 2025. The accumulated deficit as of June 30, 2026, stood at $84.4 million.

The company’s financial position showed a notable decline in cash reserves, with cash and cash equivalents decreasing to $2.05 million from $6.57 million at the end of the previous fiscal year. Total assets also fell to $6.19 million, down from $10.79 million, primarily due to a reduction in cash and cash equivalents and a decrease in the fair value of warrant liabilities. The company’s total liabilities decreased to $2.42 million from $3.71 million, reflecting a reduction in accounts payable and accrued expenses.

Strategically, NeuroOne has made significant advancements, including the completion of a limited market release of its OneRF TN Ablation System in March 2026. The company has also entered into a distribution agreement with Zimmer, Inc., which grants Zimmer exclusive rights to distribute several of NeuroOne's products, including the OneRF Ablation System. This partnership is expected to enhance product commercialization efforts, although the company has expressed concerns regarding its reliance on Zimmer for driving sales and achieving revenue milestones.

Operationally, NeuroOne has faced challenges, including a material weakness in internal controls over financial reporting, which has raised concerns about the accuracy of its financial statements. The company has acknowledged the need for improvements in its internal controls and is actively working to address these deficiencies. Additionally, the company reported that one customer accounted for 100% of its product revenue during the quarter, highlighting a significant concentration risk.

Looking ahead, NeuroOne anticipates continued operating losses as it invests in product development and commercialization efforts. The company has indicated that it will need to secure additional funding to support its operations, as its current cash reserves may not be sufficient to cover expenses for the next twelve months. The management has expressed substantial doubt about the company's ability to continue as a going concern if it cannot raise the necessary capital.